Arbutus Biopharma Corp operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Arbutus Biopharma Corp with three other companies in this sector in CANADA : Liminal BioSciences Inc (2019 sales of 4.90 million Canadian Dollars [US$3.68 million] of which 97% was Plasma derived therapeutics), Antibe Therapeutics Inc (9.54 million Canadian Dollars [US$7.15 million] ), and Pond Technologies Holdings Inc (6.14 million Canadian Dollars [US$4.60 million] of which 58% was Nutraceutical Products).

Sales Analysis. During the year ended December of 2019, sales at Arbutus Biopharma Corp were C$7.95 million (US$5.96 million). This is an increase of 3.0% versus 2018, when the company's sales were C$7.73 million. Despite this increase, sales are still well below the level achieved in 2017, when Arbutus Biopharma Corp reported sales of C$13.86 million.